The main aim of the study is to set up an observational cohort with NAFLD (Non-alcoholic fatty liver disease) at different stage of disease (from simple steatosis to cirrhosis and/or HCC-Hepatocellular carcinoma) and for comparative purpose a cohort of subjects with diabetes and/or obesity and/or other risk factors (i.e. psoriasis, IBD (inflammatory bowel disease), dyslipidemia) without NAFLD in order to have a clinical phenotypical characterization and the collection of biological specimens.
We will collect clinical data, biological samples and imaging results in order to perform future cross-sectional studies and/or longitudinal studies for elucidating pathways of the disease and develop and validate biomarkers for diagnosis, prognosis and monitoring liver disease and comorbidities in order to contribute to precision medicine in this field.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥18 years
* Clinical phenotype of NAFLD (simple steatosis, NASH, metabolic cirrhosis, NAFLD-HCC) based on any of:
* Liver biopsy providing histological evidence of NAFLD or,
* Biochemical and/or radiological findings consistent with NAFLD
* Average alcohol consumption ≤21/14 units/week (males/females) in preceding 6 months and no history of sustained excessive consumption of alcohol in past 5 years.
* Clearance of HCV infection with new DAAs drugs with a SVR (sustained virological response) period \> 6 months
* Presence of risk factors for NAFLD (i.e. diabetes, metabolic syndrome, obesity, psoriasis) and absence of fatty liver at US
Exclusion Criteria:
* Refusal or inability (lack of capacity) to give informed consent.
* Average alcohol ingestion \>21/14 units/week (males/females) in preceding 6 months or history of sustained excessive consumption of alcohol in past 5 years.
* History or presence of Type 1 diabetes mellitus.
* Patients not meeting inclusion criteria or judged by the investigator to be unsuitable for inclusion in the study.
Primary outcome measure(s)
Registry creation — 35 years Set up an observational cohort with NAFLD at different stage of disease (from simple steatosis to cirrhosis and/or HCC)
Trial sites (1)
Facility
City
Region
Status
Catholic University of Rome, Fondazione Policlinico Gemelli IRCCS
Roma
Rome/lazio/italy
Recruiting
More Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
